Skip to content

Study · Randomized controlled trial · n = 52 · 2002

4 results

Recombinant human growth hormone post-renal transplantation in children: a randomized controlled study of the NAPRTCS.

Fine RN, Stablein D, Cohen AH, Tejani A, Kohaut E

Kidney international1 Aug 2002Cited by 68 (Europe PMC)

PMID12110034 (opens in a new tab)DOI10.1046/j.1523-1755.2002.00489.x (opens in a new tab)PepBankPUB-12110034
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In pediatric renal allograft recipients, height SDS changed by +0.49 +/- 0.10 with rhGH versus -0.10 +/- 0.08 in controls (P < 0.001).

    In plain wordsIn children with renal transplants, rhGH increased standardized height more than control.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight SDS change
    Study

    n = 52

    Comparator
    Control
    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated · One yearAs given in this study (human).

    Measurements

    Delta height SDS
    0.49 SDS
    rhGH group (N = 30), +/- 0.10
    Delta height SDS
    −0.1 SDS
    control group (N = 22), +/- 0.08

    Source sentences

    Summary
    After one year, the delta SDS (standardized height) was +0.49 +/- 0.10 in the treatment group (N = 30) compared to -0.10 +/- 0.08 in the control group (N = 22; P < 0.001).
    1 context sentence
    Summary · context
    Sixty-eight growth retarded pediatric renal allograft recipients were enrolled in a one-year randomized controlled study to determine the efficacy and safety of rhGH.
  2. 02HumanRandomized controlled trialSafety outcome

    In pediatric renal allograft recipients, no rejection episodes occurred with rhGH during the first year versus three episodes in controls.

    In plain wordsIn children with renal transplants, no first-year rejection episodes occurred with rhGH versus three episodes in controls.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseFirst-year rejection
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated · One yearAs given in this study (human).

    Measurements

    Rejection episodes in first year
    3 episodes
    control group

    Source sentences

    Summary
    During the first year, there were no rejection episodes in the treatment group and three in the control group.
    1 context sentence
    Summary · context
    Sixty-eight growth retarded pediatric renal allograft recipients were enrolled in a one-year randomized controlled study to determine the efficacy and safety of rhGH.
  3. 03HumanRandomized controlled trialSafety outcome

    In pediatric renal allograft recipients, adverse events did not differ between rhGH and control groups.

    In plain wordsIn children with renal transplants, adverse events did not differ between rhGH and control groups.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeAdverse events
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · One yearAs given in this study (human).

    Source sentences

    Summary
    There was no difference in adverse events between the two groups.
    1 context sentence
    Summary · context
    Sixty-eight growth retarded pediatric renal allograft recipients were enrolled in a one-year randomized controlled study to determine the efficacy and safety of rhGH.
  4. 04HumanNon-randomized trialSafety outcome

    After the first year, when all pediatric recipients received rhGH, acute rejection affected three original treatment patients and two original controls.

    In plain wordsWhen all children received rhGH after the first year, acute rejection affected three original treatment patients and two original controls.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableAcute rejection after first year
    Study

    n: not reported in source

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Acute rejection after first year
    3 patients
    original treatment group, all on rhGH
    Acute rejection after first year
    2 patients
    original control group, all on rhGH

    Source sentences

    Summary
    After the first year, when all recipients were receiving rhGH, there were three patients in the treatment group and two patients in the control group who experienced an acute rejection episode.
    1 context sentence
    Summary · context
    Sixty-eight growth retarded pediatric renal allograft recipients were enrolled in a one-year randomized controlled study to determine the efficacy and safety of rhGH.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.